Literature DB >> 24529372

Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.

Kotaro Ohnishi1, Katsunori Semi2, Takuya Yamamoto2, Masahito Shimizu3, Akito Tanaka4, Kanae Mitsunaga4, Keisuke Okita4, Kenji Osafune4, Yuko Arioka4, Toshiyuki Maeda5, Hidenobu Soejima5, Hisataka Moriwaki3, Shinya Yamanaka6, Knut Woltjen7, Yasuhiro Yamada8.   

Abstract

Cancer is believed to arise primarily through accumulation of genetic mutations. Although induced pluripotent stem cell (iPSC) generation does not require changes in genomic sequence, iPSCs acquire unlimited growth potential, a characteristic shared with cancer cells. Here, we describe a murine system in which reprogramming factor expression in vivo can be controlled temporally with doxycycline (Dox). Notably, transient expression of reprogramming factors in vivo results in tumor development in various tissues consisting of undifferentiated dysplastic cells exhibiting global changes in DNA methylation patterns. The Dox-withdrawn tumors arising in the kidney share a number of characteristics with Wilms tumor, a common pediatric kidney cancer. We also demonstrate that iPSCs derived from Dox-withdrawn kidney tumor cells give rise to nonneoplastic kidney cells in mice, proving that they have not undergone irreversible genetic transformation. These findings suggest that epigenetic regulation associated with iPSC derivation may drive development of particular types of cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24529372     DOI: 10.1016/j.cell.2014.01.005

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  164 in total

Review 1.  Present and future challenges of induced pluripotent stem cells.

Authors:  Mari Ohnuki; Kazutoshi Takahashi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

Review 2.  Tissue Engineering and Regenerative Medicine 2015: A Year in Review.

Authors:  Holly Wobma; Gordana Vunjak-Novakovic
Journal:  Tissue Eng Part B Rev       Date:  2016-02-23       Impact factor: 6.389

3.  The XEN of reprogramming.

Authors:  Ergin Beyret; Juan Carlos Izpisua Belmonte
Journal:  Cell Res       Date:  2016-01-22       Impact factor: 25.617

4.  Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions.

Authors:  Jaroslav Slamecka; Lilia Salimova; Steven McClellan; Mathieu van Kelle; Debora Kehl; Javier Laurini; Paolo Cinelli; Laurie Owen; Simon P Hoerstrup; Benedikt Weber
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 5.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

6.  Derivation of ground-state female ES cells maintaining gamete-derived DNA methylation.

Authors:  Masaki Yagi; Satoshi Kishigami; Akito Tanaka; Katsunori Semi; Eiji Mizutani; Sayaka Wakayama; Teruhiko Wakayama; Takuya Yamamoto; Yasuhiro Yamada
Journal:  Nature       Date:  2017-07-26       Impact factor: 49.962

7.  Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Kendell Clement; Michael J Ziller; Patrick Boyle; Jean Fan; Hongcang Gu; Kristen Stevenson; Carrie Sougnez; Lili Wang; Shuqiang Li; Dylan Kotliar; Wandi Zhang; Mahmoud Ghandi; Levi Garraway; Stacey M Fernandes; Kenneth J Livak; Stacey Gabriel; Andreas Gnirke; Eric S Lander; Jennifer R Brown; Donna Neuberg; Peter V Kharchenko; Nir Hacohen; Gad Getz; Alexander Meissner; Catherine J Wu
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

Review 8.  Environmental exposures, stem cells, and cancer.

Authors:  Tasha Thong; Chanese A Forté; Evan M Hill; Justin A Colacino
Journal:  Pharmacol Ther       Date:  2019-07-31       Impact factor: 12.310

Review 9.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

Review 10.  Control of cancer formation by intrinsic genetic noise and microenvironmental cues.

Authors:  Amy Brock; Silva Krause; Donald E Ingber
Journal:  Nat Rev Cancer       Date:  2015-07-09       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.